Data from a third long-term study, ADAPT (The Alzheimer's Disease Anti-inflammatory Prevention Trial), did not show a significantly increased cardiovascular risk with celecoxib 200mg BID compared to placebo.
I dati provenienti da un terzo studio a lungo termine, ADAPT (The Alzheimer’ s Disease Antiinflammatory Prevention Trial), non hanno mostrato un aumento significativo del rischio cardiovascolare con celecoxib 200 mg due volte al giorno rispetto al placebo.